Waning antibody response and cellular immunity 6 months after third dose SARS‐Cov‐2 mRNA BNT162b2 vaccine in kidney transplant recipients.

2022 ◽  
Author(s):  
Dominique Bertrand ◽  
Veronique Lemée ◽  
Charlotte Laurent ◽  
Mathilde Lemoine ◽  
Mélanie Hanoy ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Cellular Immunity ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Safety and Antibody Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Kidney Transplant Recipients

2021 ◽  
Vol 05 (04) ◽  
Author(s):  
Ali AlShaqaq ◽  
Maher AlDemerdash ◽  
Abdulnaser AlAbadi ◽  
Baher Elgadaa ◽  
Najib Musaied ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients

2006 ◽  
Vol 120 (3) ◽  
pp. 342-348 ◽  
Author(s):  
Monika Lindemann ◽  
Oliver Witzke ◽  
Peter Lütkes ◽  
Melanie Fiedler ◽  
Ernst Kreuzfelder ◽  
...  
Keyword(s):  
Influenza Vaccination ◽  
Kidney Transplant ◽  
Cellular Immunity ◽  
Elispot Assay ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Sensitive Tool

scholarly journals Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients

2021 ◽  
Author(s):  
Roman Reindl-Schwaighofer ◽  
Andreas Heinzel ◽  
Manuel Mayrdorfer ◽  
Rhea Jabbour ◽  
Thomas M. Hofbauer ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Vaccine Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1438
Author(s):  
Anja Gäckler ◽  
Nils Mülling ◽  
Kim Völk ◽  
Benjamin Wilde ◽  
Ute Eisenberger ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Cellular Immunity ◽  
Elispot Assay ◽  
Pneumococcal Infection ◽  
Organ Transplant ◽  
Pneumococcal Vaccination ◽  
Cellular Responses ◽  
Interferon Γ ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

In organ transplant recipients, the rate of invasive pneumococcal diseases is 25 times greater than in the general population. Vaccination against S. pneumoniae is recommended in this cohort because it reduces the incidence of this severe form of pneumococcal infection. Previous studies indicate that transplant recipients can produce specific antibodies after pneumococcal vaccination. However, it remains unclear if vaccination also induces specific cellular immunity. In the current study on 38 kidney transplant recipients, we established an interferon-γ ELISpot assay that can detect serotype-specific cellular responses against S. pneumoniae. The results indicate that sequential vaccination with the conjugated vaccine Prevenar 13 and the polysaccharide vaccine Pneumovax 23 led to an increase of serotype-specific cellular immunity. We observed the strongest responses against the serotypes 9N and 14, which are both components of Pneumovax 23. Cellular responses against S. pneumoniae correlated positively with specific IgG antibodies (r = 0.32, p = 0.12). In conclusion, this is the first report indicating that kidney transplant recipients can mount specific cellular responses after pneumococcal vaccination. The ELISpot we established will allow for further investigations. These could help to define, for example, factors influencing specific cellular immunity in immunocompromised cohorts or the duration of cellular immunity after vaccination.

scholarly journals Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept

2021 ◽  
Author(s):  
Nathalie Chavarot ◽  
Antoine Morel ◽  
Marianne Leruez‐Ville ◽  
Estelle Villain ◽  
Gillian Divard ◽  
...  
Keyword(s):  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation

2021 ◽  
Vol 11 (1) ◽  
pp. 148
Author(s):  
Lukas Buchwinkler ◽  
Claire Anne Solagna ◽  
Janosch Messner ◽  
Markus Pirklbauer ◽  
Michael Rudnicki ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Transplantation ◽  
Kidney Disease ◽  
Antibody Response ◽  
Kidney Transplant ◽  
Mycophenolic Acid ◽  
Calcineurin Inhibitors ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Factors Associated

Most trials on mRNA vaccines against SARS-CoV-2 did not include patients with chronic kidney disease (CKD), hemodialysis (HD) patients, or kidney transplant recipients (KTR). However, those patients have a higher risk for a severe course of COVID-19 disease and mortality. Available literature has demonstrated a reduced efficacy of mRNA vaccines in HD patients and KTR, while data on CKD patients is scarce. Additionally, factors associated with non-response are poorly understood and not well characterized. We assessed antibody (AB) response (n = 582, 160 CKD patients, 206 patients on HD, 216 KTR) after the administration of two doses of a mRNA-vaccine with either BNT162b2 or mRNA-1273. AB measurements were carried out after a median of 91 days after first vaccinations, demonstrating non-response in 12.5% of CKD patients, 12.1% of HD patients, and 50% of KTR. AB titers were significantly higher in CKD patients than in HD patients or KTR. Factors associated with non-response were treated with rituximab in CKD patients, the use of calcineurin inhibitors in HD patients and older age, and the use of BNT162b2, mycophenolic acid, or glucocorticoids and lower hemoglobin levels in KTR. This study contributes to the understanding of the extent and conditions that predispose for non-response in patients with impaired kidney function.

scholarly journals Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine

2021 ◽  
Vol 8 (1) ◽  
pp. e1257
Author(s):  
Stephanie G. Yi ◽  
Linda W. Moore ◽  
Todd Eagar ◽  
Edward A. Graviss ◽  
Duc T. Nguyen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Antibody Response ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Factors Associated
Sign in / Sign up

Export Citation Format

Share Document